Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
MeiraGTx Hldgs
(NASDAQ:MGTX)
Intraday
$4.86
-0.07
[-1.42%]
After-Hours
$4.86
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$4.86
-0.07
[-1.42%]
At close: Apr 24
$4.86
0
[0.00%]
After Hours: 4:00PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for MeiraGTx Hldgs Stock (NASDAQ:MGTX)
MeiraGTx Hldgs Stock (NASDAQ: MGTX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, March 15, 2024
RBC Capital Reiterates Outperform on MeiraGTx Hldgs, Maintains $11 Price Target
Benzinga Newsdesk
-
Mar 15, 2024, 12:23PM
Thursday, March 14, 2024
Recap: MeiraGTx Hldgs Q4 Earnings
Benzinga Insights
-
Mar 14, 2024, 5:50PM
Tuesday, February 13, 2024
MeiraGTx Announces $50M Milestone From Janssen Pharmaceuticals
Benzinga Newsdesk
-
Feb 13, 2024, 8:09AM
Thursday, December 21, 2023
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor
-
Dec 21, 2023, 1:01PM
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
Dec 21, 2023, 12:32PM
Why Is Eye Disease Related Gene Therapy Focused MeiraGTx Stock Soaring Today?
Vandana Singh
-
Dec 21, 2023, 11:11AM
MeiraGTx shares are trading higher after the company announced an asset purchase agreement involving its AAV-RPGR collaboration for up to $415 million.
Benzinga Newsdesk
-
Dec 21, 2023, 9:27AM
MeiraGTx Holdings Inked A Asset Purchase Agreement With Janssen Pharmaceuticals For Acquiring Remaining Stake In Botaretigene Sparoparvovec (Bota-vec) For The Treatment Of X-linked Retinitis Pigmentosa (XLRP) For $415M
Benzinga Newsdesk
-
Dec 21, 2023, 7:05AM
Friday, December 08, 2023
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
-
Dec 8, 2023, 4:30PM
Tuesday, November 14, 2023
MeiraGTx Hldgs: Q3 Earnings Insights
Benzinga Insights
-
Nov 14, 2023, 9:35AM
As Of September 30, 2023, MeiraGTx Had Cash And Cash Equivalents Of Approximately $64M, Which Is expected To Be Sufficient To Fund Operating Expenses And Capital Expenditure Requirements Into Mid-2025
Benzinga Newsdesk
-
Nov 14, 2023, 8:15AM
MeiraGTx Hldgs Q3 EPS $(0.74) Misses $(0.55) Estimate, Sales $5.10M Beat $3.27M Estimate
Benzinga Newsdesk
-
Nov 14, 2023, 8:14AM
Monday, October 30, 2023
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
-
Oct 30, 2023, 1:55PM
Why Is Gene Therapy Company MeiraGTx Stock Trading Higher Today?
Vandana Singh
-
Oct 30, 2023, 1:25PM
MeiraGTx Holdings shares are trading higher after the company announced Sanofi made a $30 million strategic investment through the purchase of 4 million shares at a price of $7.50 per share.
Benzinga Newsdesk
-
Oct 30, 2023, 10:35AM
MeiraGTx Announces $30M Strategic Investment from Sanofi Via Purchase of 4M Shares At $7.50/Share
Benzinga Newsdesk
-
Oct 30, 2023, 7:37AM
Tuesday, October 24, 2023
MeiraGTx Announces An Oral Presentation And Eight Posters At The European Society Of Gene And Cell Therapy 2023 Annual Congress
Benzinga Newsdesk
-
Oct 24, 2023, 8:34AM
Friday, August 11, 2023
RBC Capital Maintains Outperform on MeiraGTx Hldgs, Lowers Price Target to $11
Benzinga Newsdesk
-
Aug 11, 2023, 12:06PM
Chardan Capital Reiterates Buy on MeiraGTx Hldgs, Maintains $41 Price Target
Benzinga Newsdesk
-
Aug 11, 2023, 4:18AM
Thursday, August 10, 2023
MeiraGTx Hldgs Q2 EPS $(0.53) Up From $(0.76) YoY, Sales $3.54M Down From $10.76M YoY
Benzinga Newsdesk
-
Aug 10, 2023, 8:10AM
Tuesday, August 01, 2023
MeiraGTx Announces Poster Presentation At The 2023 American Society Of Gene And Cell Therapy Spotlight On Immuno-Oncology
Benzinga Newsdesk
-
Aug 1, 2023, 9:18AM
Wednesday, July 19, 2023
MeiraGTx shares are trading higher after the company announced it received a Commercial Manufacturer's/Importer's Authorization for its Quality Control testing facility at its GMP manufacturing site.
Benzinga Newsdesk
-
Jul 19, 2023, 11:15AM
Meiragtx Announces Its Wholly-Owned Gene Therapy Manufacturing Facility In Shannon, Ireland Has Received Commercial MIA Authorization For QC Testing
Benzinga Newsdesk
-
Jul 19, 2023, 8:35AM
Tuesday, June 27, 2023
MeiraGTx's Investigational Drug Shows Improved Symptoms In Radiation-Induced Oral Dryness
Vandana Singh
-
Jun 27, 2023, 1:41PM
Thursday, June 22, 2023
MeiraGTx Plans To Present An Update On AAV-hAQP1 Clinical Program For Treatment Of Grade 2/3 Radiation-Induced Xerostomia On June 27, 2023
Benzinga Newsdesk
-
Jun 22, 2023, 4:03PM
Tuesday, May 16, 2023
25.00M Reasons To Be Bullish On MeiraGTx Hldgs Stock
Benzinga Insights
-
May 16, 2023, 11:03AM
Over $125M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying
Lisa Levin
-
May 16, 2023, 9:08AM
Friday, May 12, 2023
Piper Sandler Maintains Overweight on MeiraGTx Hldgs, Lowers Price Target to $25
Benzinga Newsdesk
-
May 12, 2023, 9:22AM
Thursday, May 11, 2023
MeiraGTx Hldgs: Q1 Earnings Insights
Benzinga Insights
-
May 11, 2023, 9:05AM
MeiraGTx Hldgs Q1 EPS $(0.62) Beats $(0.68) Estimate, Sales $3.33M Miss $4.86M Estimate
Benzinga Newsdesk
-
May 11, 2023, 8:10AM
Wednesday, May 03, 2023
MeiraGTx Announces $60M Private Placement Of 10.7M Ordinary Shares At A Price Of $5.75/Share
Benzinga Newsdesk
-
May 3, 2023, 8:38AM
Friday, March 24, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Mar 24, 2023, 12:05PM
Thursday, March 23, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Mar 23, 2023, 1:11PM
Monday, March 20, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Mar 20, 2023, 1:29PM
Thursday, March 16, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Mar 16, 2023, 2:14PM
Chardan Capital Maintains Buy on MeiraGTx Hldgs, Lowers Price Target to $41
Benzinga Newsdesk
-
Mar 16, 2023, 7:41AM
Wednesday, March 15, 2023
MeiraGTx Holdings's Return On Capital Employed Overview
Benzinga Insights
-
Mar 15, 2023, 10:48AM
RBC Capital Maintains Outperform on MeiraGTx Hldgs, Lowers Price Target to $22
Benzinga Newsdesk
-
Mar 15, 2023, 7:58AM
Tuesday, March 14, 2023
MeiraGTx's Cash & Cash Equivalents Of $115.5M Expected To Provide Cash Runway Into Q4 Of 2024
Benzinga Newsdesk
-
Mar 14, 2023, 8:10AM
MeiraGTx Holdings FY EPS $(2.87) Misses $(2.74) Estimate, Sales $15.92M Miss $32.74M Estimate
Benzinga Newsdesk
-
Mar 14, 2023, 8:09AM
Tuesday, December 13, 2022
MeiraGTx's Investigational Candidate Shows Improvement In Radiation Induced Dry Mouth Symptoms
Vandana Singh
-
Dec 13, 2022, 1:56PM
MeiraGTx Announces 'Clinically meaningful improvements in xerostomia symptoms and disease burden reported in patient reported outcome (PRO) measures in both unilateral and bilateral cohorts'
Benzinga Newsdesk
-
Dec 13, 2022, 7:34AM
MeiraGTx Announces Clinical Data From AQUAx Phase 1 Clinical Study Of AAV2-hAQP1 For Treatment Of Grade 2/3 Radiation-Induced Xerostomia
Benzinga Newsdesk
-
Dec 13, 2022, 7:34AM
Thursday, December 08, 2022
MeiraGTx To Present Clinical Data From Phase 1 Trial Of AAV-hAQP1 For Radiation-Induced Xerostomia On Tuesday, December 13, 2022
Benzinga Newsdesk
-
Dec 8, 2022, 4:31PM
Thursday, November 10, 2022
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Nov 10, 2022, 11:29AM
Meiragtx Holdings Plc Received $25.M Investment From Johnson & Johnson Innovation - JJDC, Investment Arm Of Johnson And Johnson; Updated Topline Data From The Phase 1/2 Trial Of Botaretigene Sparoparvovec For The Treatment Of X-linked Retinitis Pigmentosa
Benzinga Newsdesk
-
Nov 10, 2022, 8:25AM
MeiraGTx Holdings Q3 EPS $(0.83) Down From $(0.59) YoY, Sales $4.82M Down From $6.95M YoY
Benzinga Newsdesk
-
Nov 10, 2022, 8:04AM
Thursday, September 29, 2022
Kiora Pharma is Starting Human Trials of a Novel Treatment That Could Restore Vision In Patients With Inherited Blindness
Rachael Green
-
Sponsored
Friday, August 12, 2022
Chardan Capital Maintains Buy on MeiraGTx Hldgs, Raises Price Target to $47
Benzinga Newsdesk
-
Aug 12, 2022, 8:53AM
Thursday, August 11, 2022
MeiraGTx Holdings Q2 EPS $0.76 Up From $(0.46) YoY
Benzinga Newsdesk
-
Aug 11, 2022, 8:32AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch